Table 1.
Intogen significantly enriched pathways
| ID | Pathway | Z score | p value | Q value |
|---|---|---|---|---|
| hsa05210 | Colorectal cancer | 8.14 | 1.88E−16 | 1.62E−14 |
| hsa05222 | Small cell lung cancer | 6.73 | 8.43E−12 | 3.63E−10 |
| hsa04150 | mTOR signalling pathway | 6.10 | 4.99E−10 | 1.43E−08 |
| hsa04310 | Wnt signalling pathway | 5.96 | 1.26E−09 | 2.71E−08 |
| hsa05212 | Pancreatic cancer | 5.77 | 3.91E−09 | 6.60E−08 |
| hsa00562 | Inositol phosphate metabolism | 5.71 | 5.37E−09 | 6.60E−08 |
| hsa04070 | Phosphatidylinositol signalling system | 5.71 | 5.37E−09 | 6.60E−08 |
| hsa04115 | p53 signalling pathway | 5.60 | 1.01E−08 | 1.09E−07 |
| hsa05166 | Human T-cell leukemia virus 1 infection | 5.50 | 1.87E−08 | 1.79E−07 |
| hsa05169 | Epstein-Barr virus infection | 4.99 | 2.96E−07 | 2.12E−06 |
| hsa05162 | Measles | 4.99 | 2.96E−07 | 2.12E−06 |
| hsa04210 | Apoptosis | 4.99 | 2.96E−07 | 2.12E−06 |
| hsa05217 | Basal cell carcinoma | 4.66 | 1.56E−06 | 1.03E−05 |
| hsa04120 | Ubiquitin mediated proteolysis | 4.59 | 2.16E−06 | 1.33E−05 |